Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Opening Monetary Information: Your Exhaustive Manual for Finding out about Individual budget - 2Huge rotating structure of galaxies and dark matter is detected
- 3This St Nick Truly Can Advise How To Drink And Hack Your Headache
- 4Trial of pro-Palestine activist begins
- 5Putin, Netanyahu discuss Middle East in phone call, Kremlin says
- How is 'A Knight of the Seven Kingdoms' connected to 'Game of Thrones'?
- Culinary Joys: Investigating Connoisseur Cooking at Home
- How to avoid or deal with an outrageous medical bill
- Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says
- ‘Downton Abbey: The Grand Finale’ hits streaming: How to watch, cast info and everything you need to know
- 3D Printers for Specialists
- The most effective method to Move toward Compensation Conversations for Cutting edge Practice Enrolled Attendants
- What is Fusarium graminearum, the fungus a Chinese scientist pleaded guilty to smuggling into the US?
- Nurturing Hacks: Astuteness from Experienced Mothers and Fathers
